Yusuke Sonehara
Keine laufenden Positionen mehr
Profil
Yusuke Sonehara worked as a Principal at Mochida Pharmaceutical Co., Ltd., a Senior Manager at Amgen KK, and a Senior Manager-Clinical Development at Solasia Pharma KK.
He received his undergraduate and graduate degrees from Tokyo University of Science.
Ehemalige bekannte Positionen von Yusuke Sonehara
| Unternehmen | Position | Ende |
|---|---|---|
Amgen KK
 Amgen KK Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Amgen KK is a wholly owned Japanese affiliate of Amgen Inc., one of the largest independent biotechnology companies in the world. The company is based in Tokyo, Japan. Amgen KK focuses on disease areas with significant unmet medical needs, including cardiometabolic, oncological, bone, inflammation/immune and neurological diseases. Currently, approximately 600 employees engage in activities from clinical development to sales with the mission of "to serve patients – doing everything we can now, for the patients." The Japanese company was founded by Fuminori Yoshida. Amgen KK was acquired by Takeda Pharmaceutical Co., Ltd. from Amgen, Inc. on March 31, 2008 for $16.58 million. | Corporate Officer/Principal | - |
| MOCHIDA PHARMACEUTICAL CO., LTD. | Corporate Officer/Principal | - |
| SOLASIA PHARMA K.K. | Corporate Officer/Principal | - |
Ausbildung von Yusuke Sonehara
| Tokyo University of Science | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| MOCHIDA PHARMACEUTICAL CO., LTD. | Health Technology |
| SOLASIA PHARMA K.K. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Amgen KK
Amgen KK Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Amgen KK is a wholly owned Japanese affiliate of Amgen Inc., one of the largest independent biotechnology companies in the world. The company is based in Tokyo, Japan. Amgen KK focuses on disease areas with significant unmet medical needs, including cardiometabolic, oncological, bone, inflammation/immune and neurological diseases. Currently, approximately 600 employees engage in activities from clinical development to sales with the mission of "to serve patients – doing everything we can now, for the patients." The Japanese company was founded by Fuminori Yoshida. Amgen KK was acquired by Takeda Pharmaceutical Co., Ltd. from Amgen, Inc. on March 31, 2008 for $16.58 million. | Health Technology |